Sign In
Buy PFE
$26.04
+0.345 (+1.34%)
At Close: Jun 05, 2026
Pfizer (PFE) is a Top-Ranked Value Stock: Should You Buy?
10:45am, Friday, 15'th Nov 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Friday, 15'th Nov 2024
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS
04:40pm, Thursday, 14'th Nov 2024
Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and former presidential hopeful Robert F. Kennedy Jr. as his pick to lead the U.
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
10:00am, Thursday, 14'th Nov 2024
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Andrew Baum, Chief Strategy and Innovation Officer, Exe
Pfizer Inc. (PFE) UBS Global Healthcare Conference (Transcript)
07:23pm, Wednesday, 13'th Nov 2024
Pfizer Inc. (NYSE:PFE ) UBS Global Healthcare Conference November 13, 2024 3:30 PM ET Company Participants Aamir Malik - Chief Commercial Officer US Conference Call Participants Trung Huynh - UBS Trun
Buy These 5 Price-to-Book Value Stocks in November
04:01pm, Wednesday, 13'th Nov 2024
The P/B ratio helps to identify low-priced stocks with high growth prospects. PFE, GM, GBX, ITRI and STNE are some such stocks.
Down -11.04% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)
10:36am, Wednesday, 13'th Nov 2024
Pfizer (PFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
07:41pm, Tuesday, 12'th Nov 2024
Investors can see insider buys as an overall net positive concerning the longer-term outlook for a stock.
Build a Balanced Portfolio With 4 Top Value Stocks as Markets Surge
04:01pm, Tuesday, 12'th Nov 2024
Value investing is essentially about selecting stocks that are cheap but fundamentally sound. STNE, SKX, PFE and GM boast a low P/CF ratio.
Should Value Investors Buy Pfizer (PFE) Stock?
10:45am, Tuesday, 12'th Nov 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Down -9.77% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)
10:35am, Tuesday, 12'th Nov 2024
Pfizer (PFE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates cou
Exclusive: Pfizer explores sale of hospital drugs unit, sources say
09:47am, Tuesday, 12'th Nov 2024
Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three peo
5 Trusted Retirement Passive Income Dividend Stocks Every Baby Boomer Should Own
09:14am, Tuesday, 12'th Nov 2024
Key Points The 2025 Social Security COLA increase is only 2.5%.
AbbVie And Pfizer: Q3 Dividend Checkup Post-Earnings
06:45pm, Monday, 11'th Nov 2024
I review both AbbVie and Pfizer's recent earnings reports via the window of dividends following Peter Lynch's wisdom. Lynch's insights into dividend stocks are often in the shadow of his reputation as
ViiV Healthcare Announces Data Demonstrating Dovato (DTG/3TC) Is Highly Effective in Treatment-Naïve People With Advanced HIV
09:30am, Monday, 11'th Nov 2024
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 48-week findings from the DOLCE study, spon
